(VIANEWS) - The Market ended the session with CELYAD ONCOLOGY (CYAD.BR) rising 10% to €0.57 on Tuesday, following the last session's upward trend. BEL 20 dropped 0.46% to €3,699.10, following the last session's downward trend on what was a somewhat bearish trend trading session today.
About CELYAD ONCOLOGY
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, CELYAD ONCOLOGY has a trailing twelve months EPS of €-1.71.
Volatility
CELYAD ONCOLOGY's last week, last month's, and last quarter's current intraday variation average was a positive 0.79%, a negative 0.09%, and a positive 2.17%.
CELYAD ONCOLOGY's highest amplitude of average volatility was 1.37% (last week), 2.44% (last month), and 2.17% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CELYAD ONCOLOGY's stock is considered to be oversold (<=20).
More news about CELYAD ONCOLOGY (CYAD.BR).